MaxCyte (MXCT) News Today $2.61 +0.06 (+2.35%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.48 -0.13 (-4.98%) As of 04/17/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Vanguard Group Inc. Sells 345,587 Shares of MaxCyte, Inc. (NASDAQ:MXCT)Vanguard Group Inc. reduced its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,429,681 shares of the company's stock after selling 345,587April 17 at 3:09 AM | marketbeat.comPortolan Capital Management LLC Has $4.72 Million Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)Portolan Capital Management LLC reduced its stake in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 12.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,135,613 shares of the company's stock after sApril 16 at 8:11 AM | marketbeat.comMaxCyte intends to delist from London's AIM to enhance liquidityApril 15 at 5:24 PM | lse.co.ukMaxCyte to Delist from AIM, Focus on NasdaqApril 15 at 2:14 AM | tipranks.comMaxCyte, Inc. (NASDAQ:MXCT) Shares Bought by CenterBook Partners LPCenterBook Partners LP boosted its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 48.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 867,009 shares of the company'sApril 12, 2025 | marketbeat.comMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comWith 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsApril 8, 2025 | uk.finance.yahoo.comMaxCyte Expands Capital with New Stock IssuanceApril 1, 2025 | tipranks.comMaxCyte, Inc. (NASDAQ:MXCT) CFO Douglas J. Swirsky Sells 6,939 SharesMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) CFO Douglas J. Swirsky sold 6,939 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $3.18, for a total transaction of $22,066.02. Following the transaction, the chief financial officer now owns 111,811 shares of the company's stock, valued at $355,558.98. This trade represents a 5.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 21, 2025 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) CFO Sells $22,066.02 in StockMarch 21, 2025 | insidertrades.comRoyce & Associates LP Acquires 475,949 Shares of MaxCyte, Inc. (NASDAQ:MXCT)Royce & Associates LP increased its holdings in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 146.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 799,873 shares of the company's stock after buying an additional 475,949 shares during the quarMarch 20, 2025 | marketbeat.comBTIG Reaffirms Their Buy Rating on MaxCyte (MXCT)March 18, 2025 | markets.businessinsider.comMaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share PriceMarch 15, 2025 | seekingalpha.comWilliam Blair Forecasts MaxCyte's Q1 Earnings (NASDAQ:MXCT)MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Investment analysts at William Blair issued their Q1 2025 EPS estimates for shares of MaxCyte in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst M. Larew forecasts that the company will earn ($0.10) perMarch 15, 2025 | marketbeat.comWhat is William Blair's Estimate for MaxCyte Q1 Earnings?MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will post earnings per share of ($0.09) for the quarteMarch 14, 2025 | marketbeat.comStifel Nicolaus Lowers MaxCyte (NASDAQ:MXCT) Price Target to $9.00Stifel Nicolaus lowered their price target on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Wednesday.March 13, 2025 | marketbeat.comMaxCyte (NASDAQ:MXCT) Issues Earnings ResultsMaxCyte (NASDAQ:MXCT - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%.March 12, 2025 | marketbeat.comMaxCyte, Inc. (MXCT) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comMaxCyte shares tumble as Q4 revenue plunges despite beating estimatesMarch 11, 2025 | au.investing.comMaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 GuidanceMarch 11, 2025 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 GuidanceMarch 11, 2025 | globenewswire.comRiver Global Investors LLP Buys 1,190,630 Shares of MaxCyte, Inc. (NASDAQ:MXCT)River Global Investors LLP increased its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 57.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,253,192 shares of the companyMarch 9, 2025 | marketbeat.comMaxCyte Expands Stock Capital with New IssuanceMarch 4, 2025 | tipranks.comMaxCyte (MXCT) Projected to Post Quarterly Earnings on TuesdayMaxCyte (NASDAQ:MXCT) will be releasing earnings after the market closes on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=663906)March 4, 2025 | marketbeat.comRice Hall James & Associates LLC Makes New $1.10 Million Investment in MaxCyte, Inc. (NASDAQ:MXCT)Rice Hall James & Associates LLC acquired a new position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 263,833 shares of the company's stock, valuedFebruary 19, 2025 | marketbeat.comBlackRock Adjusts Holdings in MaxCyte, Inc.February 13, 2025 | tipranks.comMaxCyte, Inc: MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics ProgramsFebruary 12, 2025 | finanznachrichten.deMaxCyte enters strategic platform license with TG TherapeuticsFebruary 12, 2025 | markets.businessinsider.comMaxCyte Partners with TG Therapeutics for Autoimmune Cell TherapyFebruary 12, 2025 | tipranks.comMaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics ProgramsFebruary 12, 2025 | globenewswire.comMaxCyte, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results Release Date and Earnings Call DetailsFebruary 7, 2025 | quiverquant.comMaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor ConferenceFebruary 7, 2025 | globenewswire.comMaxCyte Share Chat (MXCT)February 2, 2025 | lse.co.ukGagnon Securities LLC Boosts Stake in MaxCyte, Inc. (NASDAQ:MXCT)Gagnon Securities LLC raised its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 234.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 197,326 shares of the company's stock after buying an additional 138,257 shares during the period.February 1, 2025 | marketbeat.comMaxCyte director exercises options, sells sharesJanuary 31, 2025 | msn.comGlancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)January 30, 2025 | businesswire.comCraig-Hallum Gives a Buy Rating to MaxCyte (MXCT)January 30, 2025 | markets.businessinsider.comMaxCyte, Inc. Acquires SeQure Dx to Enhance Cell and Gene Therapy SolutionsJanuary 30, 2025 | quiverquant.comMaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing AssessmentsJanuary 30, 2025 | globenewswire.comJohn Joseph Johnston Sells 3,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the company's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $4.64, for a total value of $13,920.00. Following the transaction, the director now directly owns 141,950 shares of the company's stock, valued at approximately $658,648. This represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.January 29, 2025 | marketbeat.comMarketBeat Week in Review – 01/20 - 01/24 (MXCT)Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earningsJanuary 25, 2025 | marketbeat.comMaxCyte (NASDAQ:MXCT) Stock Price Down 5.8% - Here's What HappenedMaxCyte (NASDAQ:MXCT) Stock Price Down 5.8% - Here's What HappenedJanuary 23, 2025 | marketbeat.comMaxCyte: Building the Future of Cell and Gene Therapy InnovationMaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.January 23, 2025 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLCBarclays PLC boosted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 329.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 165,765 shares of the company's stock after buying an additional 127January 17, 2025 | marketbeat.comBlackRock Increases Stake in MaxCyte, Inc.January 15, 2025 | tipranks.comMaxCyte (MXCT) Receives a Buy from Craig-HallumJanuary 14, 2025 | markets.businessinsider.comDavid I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) General Counsel David I. Sandoval sold 4,466 shares of the firm's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $4.54, for a total transaction of $20,275.64. Following the completion of the sale, the general counsel now owns 41,447 shares in the company, valued at approximately $188,169.38. The trade was a 9.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.January 14, 2025 | marketbeat.comMaxCyte (NASDAQ:MXCT) Shares Up 8.2% - Here's WhyMaxCyte (NASDAQ:MXCT) Trading Up 8.2% - Should You Buy?January 13, 2025 | marketbeat.comMaxCyte, Inc: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial ResultsJanuary 13, 2025 | finanznachrichten.de Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Media Mentions By Week MXCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼0.650.49▲Average Medical News Sentiment MXCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼52▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TaskUs News Sezzle News OLO News Paysafe News Fiverr International News Radware News Custom Truck One Source News i3 Verticals News Tremor International News Yext News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MXCT) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MXCT Stock Free MXCT Stock Alerts